| Brand Name | Ilumya |
| Generic Name | Tildrakizumab |
| Drug Class | Anti-IL-12/IL-23 Monoclonal Antibody |
| Availability | Prescription |
| Manufacturer | Merck & Co. |
| Indications | Ulcerative Colitis, Crohn's Disease |
| Type | Injection |
| Doses | 100 mg at weeks 0, 4, then every 12 weeks for maintenance. |
| Route | Subcutaneous |
| Side Effects | Injection site pain, upper respiratory infections, diarrhea |
| Interactions | IL-23 inhibitor; monitor for infections and hypersensitivity |
| Overdose | Infections, injection-site reactions. |
| Missed Dose | Take ASAP or at next scheduled dose. |
| Contraindications | Hypersensitivity, active infection, caution in liver disease. |
| Alternatives | Vedolizumab |
| Co-Pay Assistance Program | Available Rx |
| Patient Assistance Program | Available |
Dr. Bharat Pothuri is a Board-Certified Gastroenterologist and Hepatologist. With extensive experience in digestive health, he specializes in advanced endoscopic procedures, chronic GI disorder management, and preventive care. Dr. Pothuri is dedicated to providing expert, patient-focused insights to help improve gut health and overall well-being.
Tildrakizumab is used to treat moderate to severe plaque psoriasis by inhibiting interleukin-23 (IL-23) to reduce inflammation in the skin.
Tildrakizumab works by targeting IL-23, a protein involved in the inflammatory process, thereby reducing the overproduction of skin cells that causes psoriasis flare-ups.
Common side effects include upper respiratory infections, headache, and fatigue. Serious side effects may include infections and allergic reactions.
Tildrakizumab is administered as a subcutaneous injection, usually every 12 weeks after the initial doses. Your doctor will guide the schedule based on your response.
Yes, as an immunosuppressive drug, Tildrakizumab can increase the risk of infections. Regular monitoring by your healthcare provider is necessary to detect and treat infections promptly.
Tildrakizumab should only be used during pregnancy if the potential benefits outweigh the risks. Consult your healthcare provider if you are pregnant or planning to become pregnant.
Tildrakizumab has been shown to be highly effective in treating moderate to severe plaque psoriasis, with many patients experiencing significant skin improvement.
If you miss a dose, contact your healthcare provider for guidance. Do not administer the medication yourself if you miss a dose.
Tildrakizumab is primarily used for psoriasis, but it is being researched for other inflammatory conditions, such as psoriatic arthritis.
Tildrakizumab may interact with other immunosuppressive medications. Always inform your healthcare provider of all medications you are taking.
Related Conditions |
Related Blogs |
|---|---|
